Red Capital invested in Imexpharm Pharmaceutical Joint Stock Company (“Imexpharm”) in 2017 when Imexpharm invested in its first EU-GMP manufacturing line. Imexpharm has always been a pioneer in producing high-quality pharmaceuticals by proactively adopting European technology in manufacturing since 1999. Currently, the company boasts the largest number of EU-GMP standard production lines in the country, with 11 EU-GMP lines across 3 factory clusters.